Proteomic analysis reveals a potential anticancer mechanism for a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin inclusion complex towards colorectal cancer cells through modulation of ribosome biogenesis
• CUR-A-Poly-β-CD has favorable characteristics and shows no cytotoxicity in a normal colon cell line. • CUR-A-Poly-β-CD induces cytotoxicity in SW-48, HT-29, and SW-480 colorectal cell lines. • CUR-A-Poly-β-CD promotes apoptosis and inhibits proliferation, clonogenicity, and migration of SW-480 cells. • Proteomic analysis identified 105 altered proteins in SW-480 cells treated with CUR-A-Poly-β-CD. • Altered proteins induced by CUR-A-Poly-β-CD are mainly involved in ribosome biogenesis. Colorectal cancer (CRC) is a major global health issue due to its aggressiveness and high mortality rates. While curcumin, the bioactive compound from turmeric ( Curcuma longa L.), exhibits anticancer properties, its low water solubility limits therapeutic potential. The present study developed a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin (CUR-A-Poly-β-CD) inclusion complex to enhance solubility and evaluated its anticancer potential in CRC cell lines. The complex exhibited a zeta potential of -22.9 ± 1.1 mV, a particle size of 496.8 ± 1.9 nm, a solubility of 13.6 mg/L, and a pH of 4.5. CUR-A-Poly-β-CD was non-toxic to normal colon cells (CCD-841 CoN) but significantly reduced the viability of CRC cell lines HT-29, SW-48, and SW-480, with SW-480 cells being the most responsive. CUR-A-Poly-β-CD induced apoptosis and inhibited proliferation, clonogenicity, and migration of SW-480 cells. Proteomic analysis identified 105 altered proteins in SW-480 cells treated with CUR-A-Poly-β-CD, primarily involved in cell growth and ribosome biogenesis pathways. Western blot analysis confirmed increased levels of ribosomal proteins RPL13a and RPS3. In conclusion, the CUR-A-Poly-β-CD inclusion complex demonstrates anticancer effects against CRC by modulating ribosome biogenesis. These findings suggest its potential as a therapeutic approach to improve the effectiveness of CRC treatments.
Authors
- Siripat Aluksanasuwan (ORCID: https://orcid.org/0000-0002-3542-5880)
- Phateep Hankittichai (ORCID: https://orcid.org/0000-0002-3777-0848)
- Wuttichai Jaidee (ORCID: https://orcid.org/0000-0002-5189-1478)
- Sasivimon Pramual (ORCID: https://orcid.org/0000-0002-0308-1614)
- Churat Weeraphan (ORCID: https://orcid.org/0009-0009-7020-5910)
- Atthapan Morchang (ORCID: https://orcid.org/0000-0001-9076-7886)
- Keerakarn Somsuan (ORCID: https://orcid.org/0000-0002-9848-8010)
- Theetat Ruangjaroon
- Arunothai Wanta (ORCID: https://orcid.org/0009-0005-2209-8314)
- Jisnuson Svasti (ORCID: https://orcid.org/0000-0002-2217-4517)
- Chantragan Srisomsap (ORCID: https://orcid.org/0000-0003-3919-2380)
- Daranee Chokchaichamnankit
- Rawiwan Charoensup (ORCID: https://orcid.org/0000-0001-6433-0293)
- Artitaya Rongjumnong
- Chanatip Pramvichai
Institutions
- Mae Fah Luang University (TH)
- Chulabhorn Research Institute (TH)
Publication Details
- Journal
- Carbohydrate Polymer Technologies and Applications
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1016/j.carpta.2025.100775
- Citations
- 1
- Primary Topic
- Curcumin's Biomedical Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.59
Funders
- Agricultural Research Development Agency
- Chulabhorn Research Institute
- Thailand Science Research and Innovation